Product Description
RX-3117 is an oral, small molecule cytidine analog anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs. The agent has excellent activity against various cancer cell lines and xenografts including gemcitabine-resistant variants and it has excellent oral bioavailability; it is not a substrate for the degradation enzyme cytidine deaminase.Ê (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30879349/)
Mechanisms of Action: DNA Mtase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Processa Pharmaceuticals
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Bladder Cancer|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03189914 |
RX3117-003 | P2 |
Completed |
Pancreatic Cancer |
2019-10-01 |
50% |
2023-12-07 |
|
NCT02030067 |
RX-3117-P1-01 | P2 |
Completed |
Bladder Cancer |
2019-07-01 |
22% |
2023-12-07 |
Patient Enrollment|Primary Endpoints|Treatments |